🧵 4. Novo Nordisk's lead over Eli Lilly's competing drug Zepbound grows as Wegovy demonstrates positive cardiac outcomes, while Zepbound focuses solely on weight loss.
You are viewing a single comment's thread from:
🧵 4. Novo Nordisk's lead over Eli Lilly's competing drug Zepbound grows as Wegovy demonstrates positive cardiac outcomes, while Zepbound focuses solely on weight loss.